for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amphastar Pharmaceuticals Inc

AMPH.OQ

Latest Trade

20.46USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.71

 - 

25.42

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.46
Open
--
Volume
--
3M AVG Volume
4.58
Today's High
--
Today's Low
--
52 Week High
25.42
52 Week Low
17.71
Shares Out (MIL)
47.23
Market Cap (MIL)
952.09
Forward P/E
59.88
Dividend (Yield %)
--

Latest Developments

More

Amphastar Pharmaceuticals Q2 GAAP Earnings Per Share $0.96

Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

Amphastar Pharma Plans To Launch Enoxaparin MDV In Q2 Of 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Industry

Biotechnology & Drugs

Contact Info

11570 6th St

+1.909.9809484

http://www.amphastar.com

Executive Leadership

Mary Ziping Luo

Chief Operating Officer, Chief Scientist and Chairman of the Board

Jason B. Shandell

President, General Counsel, Director

Jack Yongfeng Zhang

Chief Executive Officer, Chief Scientific Officer, Director

William J. Peters

Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc.

Rong Zhou

Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.2K

2018

0.3K

2019(E)

0.3K
EPS (USD)

2016

0.490

2017

0.380

2018

0.210

2019(E)

0.337
Price To Earnings (TTM)
18.93
Price To Sales (TTM)
2.94
Price To Book (MRQ)
2.45
Price To Cash Flow (TTM)
14.51
Total Debt To Equity (MRQ)
12.05
LT Debt To Equity (MRQ)
10.26
Return on Investment (TTM)
11.73
Return on Equity (TTM)
9.14

Latest News

Latest News

BRIEF-Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ

BRIEF-Amphastar Announces Approval For Sodium Nitroprusside Injection, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

BRIEF-Amphastar Pharma reports results for three months ended Sept

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017

BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

* Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04

* Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

BRIEF-Amphastar Pharmaceuticals reports Q1 earnings per share $0.02

* Amphastar Pharmaceuticals reports financial results for the three months ended march 31, 2017

BRIEF-Amphastar Pharma Q4 gaap loss per share $0.06

* Amphastar Pharmaceuticals reports financial results for the three months and fiscal year ended December 31, 2016

BRIEF-Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co

* Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co

FDA rejects Amphastar's nasal opioid overdose treatment

Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.

FDA rejects Amphastar's nasal version of opioid overdose treatment

Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the drug naloxone, which is designed to stop or reverse the effects of an opioid overdose.

BRIEF-Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose

* Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose

BRIEF-Mannkind - Enters into settlement agreement with Sanofi-Aventis

* Mannkind Corp - co, other entities entered into a settlement agreement with Sanofi-Aventis U.S. LLC - SEC filing

BRIEF-Amphastar Pharmaceuticals posts Q3 adj. earnings $0.14/shr

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up